Bioequivalence Study Between "DA-5209 Tab" and "Lixiana Tab"

NCT ID: NCT04671316

Last Updated: 2021-02-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 121 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-23
• Study Completion Date: 2021-02-04

Brief Summary

An Open-Label, Randomized, 6-sequence, 3-period, Fasting Condition, Single-dose, Per Oral, Cross-over Study to Evaluate the Bioequivalence between "DA-5209 60mg Tab" and "Lixiana 60mg Tab" in Healthy Volunteers

Detailed Description

1. Study design: An open-Label, randomized, 6-sequence, 3-period, fasting condition, single-dose, per oral, cross-over study

2. Administration method:

The subject should maintain a minimum of 10 hours of empty stomach before administration, and give an oral dose of 1 tablets (DA-5209 60mg) without water or (DA-5209 60mg or Lixiana 60mg) with 150 mL of water at around 8 a.m. on the day of the test. The subject should not chew or break the drug, but should swallow in whole with water. The difference in administration time between the test subjects is about one minute apart, considering the blood collection time.

3. Wash out period: at least 7 days

4. Blood collection time: Before the administration, 5, 10, 15, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hr after the administration (total 15 times)

5. Analysis: Measurement of the concentration of an unchangeable substance of Edoxaban in plasma

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

T1T2R

Period I: T1, "DA-5209 60mg" without water Period II: T2, "DA-5209 60mg" with 150mL water Period III: R, "Lixiana 60mg" with 150mL water

Group Type: EXPERIMENTAL

DA-5209 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5209 60mg Tab" with 150mL water

DA-5209 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5209 60mg Tab" without water

Lixiana 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "Lixiana 60mg Tab" with 150mL water

T1RT2

Period I: T1, "DA-5209 60mg" without water Period II: R, "Lixiana 60mg" with 150mL water Period III: T2, "DA-5209 60mg" with 150mL water

Group Type: EXPERIMENTAL

DA-5209 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5209 60mg Tab" with 150mL water

DA-5209 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5209 60mg Tab" without water

Lixiana 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "Lixiana 60mg Tab" with 150mL water

RT1T2

Period I: R, "Lixiana 60mg" with 150mL water Period II: T1, "DA-5209 60mg" without water Period III: T2, "DA-5209 60mg" with 150mL water

Group Type: EXPERIMENTAL

DA-5209 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5209 60mg Tab" with 150mL water

DA-5209 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5209 60mg Tab" without water

Lixiana 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "Lixiana 60mg Tab" with 150mL water

RT2T1

Period I: R, "Lixiana 60mg" with 150mL water Period II: T2, "DA-5209 60mg" with 150mL water Period III: T1, "DA-5209 60mg" without water

Group Type: EXPERIMENTAL

DA-5209 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5209 60mg Tab" with 150mL water

DA-5209 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5209 60mg Tab" without water

Lixiana 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "Lixiana 60mg Tab" with 150mL water

T2RT1

Period I: T2, "DA-5209 60mg" with 150mL water Period II: R, "Lixiana 60mg" with 150mL water Period III: T1, "DA-5209 60mg" without water

Group Type: EXPERIMENTAL

DA-5209 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5209 60mg Tab" with 150mL water

DA-5209 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5209 60mg Tab" without water

Lixiana 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "Lixiana 60mg Tab" with 150mL water

T2T1R

Period I: T2, "DA-5209 60mg" with 150mL water Period II: T1, "DA-5209 60mg" without water Period III: R, "Lixiana 60mg" with 150mL water

Group Type: EXPERIMENTAL

DA-5209 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5209 60mg Tab" with 150mL water

DA-5209 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "DA-5209 60mg Tab" without water

Lixiana 60mg Tab

Intervention Type: DRUG

single oral administration of 1 tablet of "Lixiana 60mg Tab" with 150mL water

Interventions

DA-5209 60mg Tab

single oral administration of 1 tablet of "DA-5209 60mg Tab" with 150mL water

Intervention Type: DRUG

DA-5209 60mg Tab

single oral administration of 1 tablet of "DA-5209 60mg Tab" without water

Intervention Type: DRUG

Lixiana 60mg Tab

single oral administration of 1 tablet of "Lixiana 60mg Tab" with 150mL water

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. A person who aged 19 or older at the time of screening

2. BMI of 18 to 30 (BMI calculation: kg/m2)

◦Males or Females weighing 60kg or more

3. No congenital or chronic diseases or pathological symptoms

4. A person who is judged to be suitable for the study by the investigator based on the clinical laboratory examination

5. A person who has fully understood the contents of the consent form for the study and signed the consent form voluntarily and recorded the date of signature

6. A person who agreed to use contraception from the first administration of IP to a week after the last administration of IP

Exclusion Criteria

1. A person who has taken a drug that significantly induces (e.g., barbital) or inhibits the drug metabolic enzyme within 30 days prior to the first administration of IP

2. A person who has participated in other clinical trials within six months prior to the first administration of the IP

3. A person who has had whole blood transfusion within 2 months or the apheresis within 2 weeks before the first administration of IP

4. A person who has medical history of gastric resection that can affect the drug absorption

5. A person with a history of regular alcohol intake within a month prior to the first administration of the IP:

• Male: More than 21 cups/week
• Female: More than 14 cups/week (1 cup: 50 ml of soju, 250 ml of beer, 30ml of spirits)

6. A person who is hypersensitive to any of the IP components, with clinically significant bleeding, with end-stage renal disease and have kidney dialysis, with hepatic disease related to blood coagulation disorder and clinically significant risk of bleeding, with severe liver impairment, with an increased risk of bleeding, use combination therapy with other anticoagulants, Severe hypertension factor, have undergone artificial heart valve replacement

7. A person who has medical history of mental disease

8. A person who is judged not to be suitable for the study by the investigator

9. Lactating or possibly pregnant women

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Dong-A ST Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

SeungHyun Kang, Ph.D

Role: PRINCIPAL_INVESTIGATOR

H Plus Yangji Hospital

Locations

H Plus Yangji Hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

DDS20-035BE

Identifier Type: -

Identifier Source: org_study_id